Pfizer Inc. — News

Far from "yield traps," these high-yield dividend stocks represent good value at current prices.

fool.com - 2026-07-26 15:17:00

Verizon , Kinder Morgan, Regions Financial, and KeyCorp are the four buyable Barron's Better Bets Dogs, offering high, 'safest' dividends at fair prices. Analyst forecasts project net gains of 9.62% to 21.97% for top BBB Dogs by July 2027, with average net 13.68% on the top ten. Six BBB Dogs show negative free cash flow margins, making their dividends potentially unsafe; Pfizer, ONEOK, Mid-America Apartment, Federal Realty, Williams Companies, and Entergy are flagged.

seekingalpha.com - 2026-07-26 06:27:24

Pfizer is a large and well-respected pharmaceutical company. Pfizer has been facing headwinds, leaving investors worried about the dividend.

fool.com - 2026-07-25 08:15:00

Pfizer's payout ratio looks far too high. However, the company's dividend has increased despite headwinds in recent years.

fool.com - 2026-07-23 17:00:00

Pfizer's Talzenna plus Xtandi combo wins FDA priority review for HRR gene-mutated metastatic castration-sensitive prostate cancer.

zacks.com - 2026-07-23 12:56:05

Getting kicked off the Dow Jones Industrial Average sounds like a death sentence for a stock, but a handful of booted dividend giants went on to reward patient shareholders with stunning gains and steady income streams that index investors missed out on entirely.

247wallst.com - 2026-07-23 08:13:31

ABN Amro Investment Solutions lifted its holdings in shares of Pfizer Inc. (NYSE: PFE) by 11.9% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 313,794 shares of the biopharmaceutical company's stock after purchasing an additional 33,262 shares during the quarter. ABN Amro

defenseworld.net - 2026-07-23 03:47:07

Pfizer said on Wednesday the U.S. ​Food and Drug Administration has ‌granted priority review to its application seeking expanded approval for its prostate ​cancer treatment combination.

reuters.com - 2026-07-22 16:48:21

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), in men with homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC), also known as meta.

businesswire.com - 2026-07-22 16:30:00

Healthcare is quietly becoming the value hunter's playground of 2026. While the mega cap tech trade keeps sucking up oxygen, two of the largest healthcare names in the S&P 500 are trading at forward multiples that look mispriced against their earnings power.

247wallst.com - 2026-07-22 08:00:21

Pfizer's non-oncology portfolio faced mixed Q2 trends. Eliquis and Vyndaqel sales may have risen while COVID products will have declined.

zacks.com - 2026-07-21 11:06:16

In the latest trading session, Pfizer (PFE) closed at $24.75, marking a -1.2% move from the previous day.

zacks.com - 2026-07-20 18:46:12

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

zacks.com - 2026-07-20 10:01:14

Dimensional Fund Advisors LP boosted its stake in Pfizer Inc. (NYSE: PFE) by 0.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,422,799 shares of the biopharmaceutical company's stock after purchasing an additional 293,029 shares during the quarter.

defenseworld.net - 2026-07-20 04:47:03

Pfizer has an attractive weight loss pipeline. However, it will be hard to take the lead from other companies in this fast-growing area.

fool.com - 2026-07-20 03:15:00

Pfizer is deeply out of favor today, with a historically high dividend yield of 6.9%. The company is dealing with headwinds, but they are pretty normal, and Pfizer is addressing them.

fool.com - 2026-07-19 07:15:00

Aviance Capital Partners LLC boosted its holdings in shares of Pfizer Inc. (NYSE: PFE) by 21.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 165,588 shares of the biopharmaceutical company's stock after buying an additional 29,219 shares during

defenseworld.net - 2026-07-19 04:25:48

I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics, and inflation while generating attractive income. My "ALLKA Dividend Rating" model separates quality dividend opportunities from yield traps by analyzing dividend sustainability, growth prospects, and valuation. The article explores three dividend strategies, "High-Yield Defensive," "Balanced Income," and "Pure Growth," designed for goals ranging from high yield to dividend growth.

seekingalpha.com - 2026-07-18 13:03:19

Pfizer is one of the world's largest drug makers. The company is facing typical industry headwinds as it seeks new drugs to replace older ones.

fool.com - 2026-07-18 09:15:00

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies that changed their dividends. Companies with upcoming ex-dividend dates.

seekingalpha.com - 2026-07-17 23:12:40

All three can be bought on the dip.

fool.com - 2026-07-17 01:00:00

PFE trades below key moving averages as investors weigh fading COVID sales against pipeline growth, acquisitions and a low valuation with a high dividend.

zacks.com - 2026-07-16 11:45:26

Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech

globenewswire.com - 2026-07-16 07:30:00

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Pfizer (NYSE:PFE) both closed Q1 2026 with earnings beats, yet their post-report stories look nothing alike.

247wallst.com - 2026-07-15 12:27:23

Pfizer (NYSE:PFE | PFE Price Prediction) trades at $24.25, against a Wall Street consensus price target of $28.79, which represents implied upside of almost 19%.

247wallst.com - 2026-07-15 09:10:09

These stocks offer a good mix of dividends, growth, and long-term stability.

fool.com - 2026-07-14 14:00:00

Pfizer (NYSE: PFE | PFE Price Prediction) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very different bets on the future of oncology.

247wallst.com - 2026-07-14 11:51:03

PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.

zacks.com - 2026-07-14 11:31:03

The pharma giant's yield of around 7.1% is more than six times the S&P 500 average.

fool.com - 2026-07-14 10:24:39

Voluntary pricing deals reduce uncertainty for major drugmakers. Drug pricing pressure won't affect every pharmaceutical company equally.

fool.com - 2026-07-14 05:00:00

In the latest trading session, Pfizer (PFE) closed at $24.48, marking a +1.28% move from the previous day.

zacks.com - 2026-07-13 18:45:15

Abbott Laboratories (NYSE: ABT | ABT Price Prediction) and Pfizer (NYSE: PFE) both delivered Q1 2026 beats, yet the market treats them differently.

247wallst.com - 2026-07-13 16:47:09

The Dividend Income Accelerator Portfolio emphasizes high-quality companies with sustainable dividends, strong balance sheets, and attractive valuations to optimize risk-adjusted returns. I prioritize a diversified mix of ETFs and individual stocks across sectors, balancing dividend income, growth, and capital appreciation while mitigating downside risk. Key metrics include a 3.75% weighted average dividend yield, low payout ratios, and low beta factors, supporting long-term portfolio resilience.

seekingalpha.com - 2026-07-13 13:45:49

When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset exposure, pipeline diversification, and the competitive moats protecting established treatments.

marketbeat.com - 2026-07-13 12:25:30

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 4.1%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 8%.

seekingalpha.com - 2026-07-11 08:15:00

Pfizer remains an undervalued diversification play, underperforming the benchmark but increasing 2% since prior coverage. I view PFE as a defensive holding that pays investors to maintain a cautious stance in volatile markets. PFE offers an attractive opportunity to offset AI-related risks within a broader portfolio context.

seekingalpha.com - 2026-07-11 07:09:31

July's GVAS Dogs list highlights ten fair-priced, high-yield large-cap stocks, including IRSA Inversiones, Weibo, Verizon, and AT&T, as ideal buys. Analyst targets project average net gains of 40.39% for the top ten GVAS stocks by July 2027, with risk profiles generally below market volatility. The dividend dogcatcher strategy favors stocks whose $1K dividend income exceeds share price, with 36 of 54 GVAS stocks meeting this ideal condition.

seekingalpha.com - 2026-07-11 06:01:57

Pfizer is undervalued, trading at just over 8x 2026 earnings, with a 7% dividend yield and improving core business fundamentals. Core business excluding COVID drugs grew 7% in Q1, and newly launched/acquired products, especially from Seagen, are driving robust 20%+ growth. Seagen's acquisition is reshaping PFE's growth, with Padcev leading oncology momentum and a strong cost savings program underway.

seekingalpha.com - 2026-07-11 05:45:18

Pfizer has regrouped in the GLP-1 space and is now working on a long-acting drug option. The company's update on the drug's development progress suggests it can compete with GLP-1 drugs from Eli Lilly and Novo Nordisk.

fool.com - 2026-07-10 19:15:00

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

zacks.com - 2026-07-10 13:10:26

NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor, Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant and adjuvant (before and after surgery) treatment for adult patient.

businesswire.com - 2026-07-10 11:23:00

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

zacks.com - 2026-07-10 09:56:23

McDonald's (NYSE:MCD | MCD Price Prediction) versus Pfizer (NYSE:PFE): which one deserves a place in a retirement-focused portfolio right now?

247wallst.com - 2026-07-10 08:40:47

Jim Cramer stared down a stock yielding 7% and sitting near its 52-week low, and still would not tell viewers to buy it.

247wallst.com - 2026-07-09 12:25:59

Income investors watching the calendar have a narrow window this week. Three of the market's most widely held high-yield names are about to lock their next payment rosters, and the buy-by deadlines are close enough that a delayed brokerage order could push readers a full quarter down the line before the next check clears.

247wallst.com - 2026-07-08 16:07:27

The S&P 500 keeps climbing, up nearly 9% year to date, and yet a handful of large-cap dividend payers are trading like the bull market forgot they exist.

247wallst.com - 2026-07-08 10:26:38

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

zacks.com - 2026-07-08 10:01:09

They may not remain cheap for too much longer.

fool.com - 2026-07-07 18:30:00

Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash, growing earnings, and reaffirming guidance.

247wallst.com - 2026-07-07 13:19:51

Pfizer's estimated 2026 earnings easily cover its generous dividend. But Pfizer faces a patent cliff, and cash flow didn't cover the dividend last year.

fool.com - 2026-07-07 11:45:00